Ignite Creation Date:
2024-05-06 @ 6:11 PM
Last Modification Date:
2024-10-26 @ 2:43 PM
Study NCT ID:
NCT05579353
Status:
RECRUITING
Last Update Posted:
2022-10-13
First Post:
2022-10-09
Brief Title:
The Roles of Exosomal Circ-LRBA and 451CRTC2 Signaling Axis in Colorectal Cancer
Sponsor:
Jingbo Chen
Organization:
Qianfoshan Hospital
Study Overview
Official Title:
The Roles and Molecular Mechanism of Exosomal Circ-LRBA That Regulates miR-451CRTC2 Signaling Axis in Colorectal Cancer Progression
Status:
RECRUITING
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Colorectal cancer CRC is one of the most common malignant tumors in the world Most of the patients with colorectal cancer were diagnosed in poor stage Although 40 to 50 patients of colorectal cancer can be cured by surgery but most patients have undergent metastasis or recurrence and eventually death In recent years molecular targeted therapy has shown significant efficacy in specific patients It was necessary to detect the corresponding molecular targets of tumors before selecting appropriate targeted drugs in clinic The changing state of related gene molecules in colorectal cancer played a key role in drug selection there were few effective targets so far At present metastasis and recurrence still be the most difficult problems in treatment Therefore investigators should deeply study the occurrence and development of colorectal cancer at the gene level and look for new biomarkers to predict the prognosis Furthermore the study can clarify the exact molecular mechanism of colorectal cancer These will be important clinical significance for targeted therapy of colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None